Rational Pharmacotherapy in Cardiology

Advanced search

Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine

Full Text:


The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA) in patients with COVID-19 is analyzed in the article. There is controversy over the hypothesis that these drugs can be factors contributing to an unfavorable outcome of a viral disease, as well as the absence of any clinical evidence for this hypothesis. The opinion that withdrawal of ACE inhibitors and ARA in patients with COVID-19 may increase the risk of adverse outcomes is presented.

About the Author

S. Yu. Martsevich
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Sergey Yu. Martsevich – MD, PhD, Professor, Head of Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990 Russia


1. Russian statistical yearbook. Moscow: Rosstat; 2019 (In Russ.)

2. Yu C.M. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82:140-4. DOI:10.1136/pgmj.2005.037515.

3. Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and cardiovascular system: acute and long-term complications. Eur Heart J. 2020; DOI:10.1093/eurheartj/ehaa231.

4. Libby P., Simon D.L. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718-20. DOI:10.1161/01.cir.103.13.1718.

5. Fedson D.S., Rordam O.M. Testing Ebola patients: a “bottom up” approach using generic statins and angiotensin receptor blockers. Int J Infect Dis. 2015;36:80-4.

6. Fedson D.S., Opal S., Rordam O.M. Hiding in plain sight: an approach to treating patients with severe COVID-10 infection. mBio. 11:e00398-20. DOI:10.1128/mBio.00398-20.

7. Sommerstein R., Grani C. Rapid response: re: preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ. 2020;368:m810.

8. Diaz J.H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020 Mar 18. pii: taaa041. DOI:10.1093/jtm/taaa041.

9. Guan W., Ni Z., Liang W., et al. Clinical characteristics of coronavirus disease in China. N Engl J Med. 2020, February 28. DOI:10.1056/MEJMoa2002032.

10. Aronson J.K., Ferner R.E. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 [cited by April 14, 2020]. Available from:

11. Aronson J.A., Ferner R.E. Drugs and the renin-angiotensin system in covid-19. BMJ. 2020;369:m1313. DOI:10.1136/bmj.m1313.

12. Sarzani R. Relationship between COVID-19 and rennin-angiotensin-aldosterone-system blockers: hasty speculations may be dangerous. BMJ. 2020;368:m810.

13. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Disc Res. 2020. DOI:10.1002/ddr.21656.

14. Kuster G., Pfister O., Burkard T., et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020 Mar 20. pii: ehaa235. DOI:10.1093/eurheartj/ehaa235.

15. Vaduganathan M., Vardeny O., Michel T., et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Mar 30. DOI:10.1056/NEJMsr2005760.

16. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers [cited by April 14, 2020]. Available from:


For citations:

Martsevich S.Yu. Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine. Rational Pharmacotherapy in Cardiology. 2020;16(2):273-276. (In Russ.)

Views: 557

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)